Skip to content
‹ Back to IndustriesSciences

The Hidden Roadblocks to Smarter Hospitals

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle. This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care. Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · · Ai in HospitalsAndrew LamkinBikram DayClinical Data
Share

Key takeaways

01

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle.

02

This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care.

03

Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day,…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As hospitals look to improve outcomes with faster, more informed decisions, infrastructure limitations remain a major hurdle. This episode—part two of a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring—dives into what’s holding back smarter, more connected care. Intel’s Andrew Lamkin, AI Solutions Architect, and Bikram Day, Director of Informatics at Medical Informatics Corp., join Michelle Dawn Mooney to unpack the technical and clinical roadblocks buried deep in hospital systems today.

According to Day, the problem starts at the edge: “Most devices in the environment are not even connected. You end up with all that data going down a black hole.” Despite the availability of rich clinical data, fragmented device ecosystems and legacy workflows keep critical insights from reaching providers in time. Lamkin adds that while continuous monitoring has improved, infrastructure hasn’t kept pace with what’s possible: “Hospitals have networks and computing resources… we’re not talking about something that’s too high throughput to even start the conversation.”

The discussion emphasizes that many monitoring systems are still designed around outdated processes. “Almost all the infrastructure… has been there to replicate the manual charting,” Day explains. This manual-first mindset leads to hidden work for clinicians—connecting cables, hunting down data, and relying on telemetry stations that don’t scale. “We have way too many cables connecting things,” he says, but progress is happening with newer wireless sensors and shared protocols for devices like infusion pumps.

What’s needed to break through? Interoperability, automation, and rethinking the role of metadata. “Who, where, and when—all those factors are critical,” Day stresses, especially when preparing data for AI. Looking ahead, he calls for a mindset shift: “Use the human bandwidth for what the human is really good at… let the machines do their thing, which is crunching a whole bunch of data.”

Learn more about patient monitoring innovation by connecting with Andrew Lamkin and Bikram Day on LinkedIn, or by visiting Medical Informatics Corp. and Intel Health and Life Sciences.

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Network and Edge Solutions Group.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

The quantum cascade laser market is projected to grow 8% to 12% a year through 2035, driven by mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical quality checks. In these uses, the lasers offer high spectral brightness and run at room temperature in compact form factors. The installed base of analytical instruments is also growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Why shared auto-injectors keep forcing rebuilt device files

Why shared auto-injectors keep forcing rebuilt device files

Vertex Knight co-founder Fubin Wu cites digitalization, personalization and large-volume delivery as trends reshaping drug delivery devices, arguing structured data can enable reuse and cut duplicated design-file work for shared auto-injectors. ISPE says no regulatory pathway exists for platform devices, and ONdrugDelivery counts 182 large-volume subcutaneous biologics, about 15% of IV and SC agents.

  • 01A device shared across drug products still triggers repeated design control work for each new combination product, and ISPE's November 2025 article says no regulatory pathway yet exists to approve a platform device.
  • 02FDA's May 2024 draft platform technology designation under section 506K is written for drug product applications, so device design files sit outside it.
  • 03Large-volume subcutaneous biologics above 2 mL numbered 182 in a January 2025 ONdrugDelivery review, about 15% of IV and SC agents; Advanced Drug Delivery Reviews reported in July 2026 that volumes up to 25 mL are now pursued.

Oct 22, 2026

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink's Pingshan prefilled syringe plant in Shenzhen won the Innovation (Novel Technology) category at ISPE's 2026 Facility of the Year Awards. In the transcript ISPE posted with its podcast, CaiXue Wei describes vertical design, AGV-assisted transfer, AI inspection and 5G-MEC as one integrated system built around a 330 million-syringe annual capacity; Hepalink's own release adds a 24-meter warehouse, sub-10 millisecond 5G and 24,000-unit-an-hour inspection.

  • 01Hepalink's 24-meter automated warehouse raised space utilization 52 percent over a traditional layout on a land-scarce Shenzhen site supporting 330 million syringes a year.
  • 02AGVs pass material through vaporized hydrogen peroxide chambers straight into Grade A isolators, and Hepalink credits the zero-touch flow for a 100 percent first media fill.

Oct 22, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512